Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 1/20 | 0.51 |
| ▸ | CHRNG | P07510 | 1/20 | 0.51 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | CHRND | Q07001 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7839920 | 0.94 | CHRNA1 (0.47) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL3527319 | 0.86 | LMNA (0.51) | CA12CA1CA2CA9CA14 | |
| SCHEMBL13948752 | 0.84 | GABRA1 (0.48) | CA12CA1CA2CA9CA14 | |
| SCHEMBL1028144 | 0.83 | ALOX15 (0.48) | CA12CA1CA2CA9CA14 | |
| SCHEMBL17495245 | 0.83 | CA12 (0.46) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL2609133 | 0.83 | CA12 (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL24619898 | 0.81 | CA12 (0.45) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL15557828 | 0.81 | STAT3 (0.47) | CA12CA1CA2CA9CA14 | |
| SCHEMBL29388368 | 0.81 | CA12 (0.45) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL17864531 | 0.81 | CA12 (0.45) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114044905-B | Preparation method of end-group functionalized polydimethylsiloxane | 复旦大学 | 2023-01-06 | — | — | CN | claimed |
| CN-114044905-A | Preparation method of end group functionalized polydimethylsiloxane | 复旦大学 | 2022-02-15 | — | — | CN | claimed |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| EP-3233842-B1 | BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARB) AGONISTS | KING S COLLEGE LONDON (GB) | 2025-03-26 | — | — | EP | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| EP-3431480-B1 | DIARYLAMINE-BASED FLUOROGENIC PROBES FOR DETECTION OF PEROXYNITRITE | UNIV HONG KONG (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-3431480-B1 | DIARYLAMINE-BASED FLUOROGENIC PROBES FOR DETECTION OF PEROXYNITRITE | UNIV HONG KONG (CN) | 2024-07-03 | — | — | EP | disclosed |
| EP-2970342-B1 | SUBSTITUTED SILAXANTHENIUM RED TO NEAR-INFRARED FLUOROCHROMES FOR IN VITRO AND IN VIVO IMAGING AND DETECTION | VISEN MEDICAL INC (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-116854681-A | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| EP-1429759-A4 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6770666-B2 | A THERAPEUTIC AGENT FOR TREATING HEPATITIS C, BASED ON POLYMERASE INHIBITORY ACTIVITY | JAPAN TOBACCO INC. (JP) | 2004-08-03 | — | — | US | disclosed |
| EP-1429759-A2 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | Bristol-Myers Squibb Company (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040097438-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1400241-A1 | FUSED CYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-20030134853-A1 | Compounds useful for treating hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-17 | — | — | US | disclosed |
| WO-2003026587-A2 | COMPOUNDS USEFUL FOR TREATING HEPATITUS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | FXR1, FXR2, NR1H4 | CHRNA1 1927/4885CHRNG 1641/4885CHRNB1 2178/4885 |
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | HAVCR2, ZC3HAV1, POLR1C | CHRNA1 4795/4885CHRNG 4861/4885CHRNB1 4836/4885 |
| US-12404274-B2 | Macrocycles as factor xia inhibitors | TFPI, TFPI2, F11 | CHRNA1 4231/4885CHRNG 4694/4885CHRNB1 4359/4885 |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, HLA-C | CHRNA1 4657/4885CHRNG 4818/4885CHRNB1 4825/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | CHRNA1 1259/4885CHRNG 1428/4885CHRNB1 2209/4885 |
| US-20040097438-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, SLC10A1 | CHRNA1 4651/4885CHRNG 4799/4885CHRNB1 4830/4885 |
| US-20030134853-A1 | Compounds useful for treating hepatitis C virus | OAT, HAVCR2, GOT1 | CHRNA1 4606/4885CHRNG 4640/4885CHRNB1 4703/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | CHRNA1 1259/4885CHRNG 1428/4885CHRNB1 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.